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saccharum saturni) and water developed by the physician 
Antonio Guaineri, was used for many pathological 
conditions.7
In the 16th century, the Swiss physician and alchemist 
Paracelsus strongly promoted the use of metals in the 
treatment of different diseases. Among these, mercury, 
antimony, gold, copper, and lead became the subject 
of interest and experimentation by the iatrochemical 
physicians.8
Although an external use of lead acetate, in particular, 
was more common, there is clear evidence of the internal 
use of the compound in the writings of Renaissance and 
Modern age physicians.9 Lead acetate was used to stop 
diarrhoea and gut haemorrhages. In fact, sugar of lead 
acetate and copper, considered astringent substances, 
were used orally in the 16th century medicine and later, in 
particular by followers of Paracelsus, to cure the intestinal 
bleeding and diarrhoea.10
It is possible that Luigi Carafa, who had an advanced 
stage of the cancer that is likely to have caused melaena, 
was treated with a similar potion, which explains the 
extraordinaryly unique preser vation of the intestinal 
tissues and the perfect histological picture of the colon 
adenocarcinoma. This case represents one of those 
very rare instances in which direct evidence of ancient 
medicine can be gained from accurate ancient body 
examination.
*Antonio Fornaciari, Raffaele Gaeta, Silvio Chericoni, 
Fabio Stefanelli, Antonio Giuseppe Naccarato, 
Maura Castagna, Riccardo Lencioni, Valentina Giuffra, 
Gino Fornaciari
Staining Interpretation Positivity
Pan cytokeratin Cytoplasmic Epithelial cells ++
Cytokeratin 20 Cytoplasmic Colorectal, bile duct, pancreas, 
gastric cells
+++
CDX2 Membranous or cytoplasmic Colorectal cells +++
Cytokeratin 7 Cytoplasmic Negative in colonic cells –
CD10 Membranous or cytoplasmic Colon, pancreas, and prostate 
carcinoma
++
Ki67 Nuclear Cell proliferation ++
HER2 Membranous or cytoplasmic Neoplastic progression –
p53 Nuclear or cytoplasmic Tumour suppressor gene ++
++ indicates strong positivity, +++ very strong positivity, and – negativity.
Table: Immunohistochemistry of the tumour cells
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Cancer is a systemic disease and more than 90% of 
patients with cancer are dying of metastasis while 
radiotherapy is being used as the loco-regional 
treatment. This issue has been the formidable challenge 
of radiotherapy for more than a century, having an effect 
on locoregional control, but no or limited effect on 
overall survival. The high-quality translational work and 
a randomised phase 3 trial in non-small cell lung cancer 
comparing immuno therapy with standard of care have 
been game changers. Durvalumab significantly prolonged 
overall survival compared with placebo (stratified hazard 
ratio for death 0·68; p=0·0025).
So, is this the definitive solution? Should we just use 
this unchanged chemoradiotherapy protocol followed by 
the standard checkpoint inhibitors a few weeks later? My 
answer to this last question is no, because I believe that 
immunotherapy will really change radiation oncology. 
Immunotherapy is a paradigm changer in oncology, 
although the long-term cure is still unacceptably low. 
Combining immunotherapy with a proven therapeutic 
approach is obvious and radiotherapy looks to be ideally 
suited to this role for several reasons: primarily because of 
its known safety profile, but also its capacity to mediate 
robust immunostimulatory effects, which might be able to 
aid immunotherapy in achieving systemic tumour control.
There are several arguments to investigate fundamental 
changes of current radiation oncology practice. Nowadays, 
it is assumed that radiotherapy is, in the long term, most 
effective when it causes tumour-targeting immune 
responses. As a consequence, radiotherapy could be 
administered in doses and schedules that stimulate 
anticancer immunity rather than kill cancer cells through 
DNA damage. But we know that the combination of 
radiotherapy with immunotherapy has a systemic effect, 
improving the overall survival in non-small-cell lung cancer 
(PACIFIC trial). 
Strong (pre)clinical evidence suggests that key effectors 
of immunotherapy are CD8-positive lymphocytes. 
Irradiation of large blood vessels, the heart, and lymphoid 
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organs (including nodes, spleen, bone marrow, and 
thymus) can cause lymphopenia. We propose that, 
whenever possible, lymphocytes should be spared (in a 
process we named Lymphocytes-Sparing Radiotherapy; eg, 
large vessels should be an organ at risk). Draining lymph 
nodes are the main sites of T-cell cross-priming by dendritic 
cells crucial for the initiation of antitumour immune 
responses. Therefore, prophylactic irradiation of the nodes 
should be avoided. Some trials have shown that avoiding 
the irradiation of PET negative nodes does not worsen the 
results.
Typically, the dose even in routine clinical practice 
for curative treatment is just below the maximum 
tolerated dose to maximise the direct killing effect 
of radiation through DNA damage. When combined 
with immunotherapy, the objective is no longer to 
maximise DNA damage of the tumour, but to maximise 
the synergistic combination with immuno therapy. This 
approach gives us opportunities to find the optimal 
therapeutic window for each disease. Some data, for 
example, show that radiotherapy appears to sensitise 
certain types of antigen negative tumours and that 
fractionation can have a negative effect by killing 
intratumoural CD8-positive cells. With immunotherapy 
combination, there is a case for hypofractionation with 
immunogenic dose per fraction around 8 Gy.
In conventional radiotherapy, the whole tumour is 
irradiated with different margins for microscopic disease 
uncertainties. Although some clinical and preclinical 
studies show that non-irradiated tumours can be cured by 
abscopal effect and that partial cancer irradiation can also 
have a curative effect. Therefore, these textbook concepts 
might have to be revisited, particularly in the case of 
reirradiation.
Some arguments are more strategic. Typically, in 
standard therapies, the care giver is lagging behind the 
events: a treatment is started when tumour recurs. The 
effect with immunotherapy is different: immuno therapy 
has an anticancer immune response to yield a long-term 
response beyond treatment discontinuation (the so-called 
vaccination effect). This effect is due to memory cells that 
can be reactivated and this translates to a tail seen at the 
end of the survival curve.
There are other immunotherapy approaches that work 
better than checkpoint inhibitors with radiotherapy: it 
is clear that, in monotherapy, the checkpoint inhibitors 
are the leading immunotherapeutics in oncology. 
However, this success as monotherapy does not imply 
that these checkpoint inhibitors would be the best 
option in combination with radiotherapy. For example, 
in our preclinical and clinical work (NCT02086721 and 
NCT03705403) with immunocytokines, we found that 
a press-the-accelerator approach rather than a release-
the-break approach has a higher synergistic effect with 
radiotherapy, implying that checkpoint inhibitions are not 
necessarily the optimal choice in combination treatment.
Many new immunotherapeutics will come into the clinic. It 
will be crucial to develop biomarkers specific for combination 
of immunotherapy and radiotherapy to select the right 
patient population and avoid unnecessary toxicity and cost.
In preclinical studies, the immune system has been shown 
to participate in the therapeutic effect of radiotherapy, 
as well as being instrumental to the acute and chronic 
toxicities of radiotherapy. We need to do more mechanistic 
research: we cannot delegate this type of research to other 
specialists. The radiotherapy community has to take on its 
responsibilities. Finally, immunotherapy should be part of 
the basic curriculum of a young radiation oncologist.
In summary, radiation oncology is at an important 
moment of its life time; we should embrace the 
opportunity rather than resist it for the greater benefit 
of science and our patients. The new framework will be 
redesigning the way radiotherapy is delivered to interact 
most optimally with immunotherapy rather than directly 
killing as many cells as possible with radiation.
Counter opinion: Not yet
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During the past 5 years, immunotherapy has become an 
established anticancer treatment. Immune checkpoint 
inhibitors have rapidly shown effectiveness in many, but 
not all, types of tumours. Typically, remission in metastatic 
disease occurs in about 20% of patients with some 
responses being durable and potentially even curative. 
Although these results are impressive, the majority 
of tumours so far do not respond to immunotherapy 
and side-effects are not uncommon. Additionally, 
immunotherapy is, at present, very expensive and not 
available to many patients with cancer worldwide. Further 
research is needed to better understand the interactions 
of the immune system with tumours, mechanisms 
of resistance against immunotherapy, and predictive 
biomarkers. New and more efficacious immunotherapy 
strategies need to be developed. Finally, immunotherapy 
needs to be efficiently integrated with other current 
anticancer treatments, including radio therapy.
It is well recognised that radiation can evoke stimulatory 
or suppressive immune effects. The biological mechanisms 
underlying these effects are not fully understood yet. 
In preclinical models, radiation-associated immune 
stimulatory effects on tumours are variable, depending 
on the tumour model, and radiotherapy dose and 
fractionation. The combination of checkpoint inhibitors 
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with radiotherapy to further increase tumour response 
has gained substantial interest. This approach is spurred 
by preclinical and clinical reports showing remarkable 
responses or abscopal effects (response also of non-
irradiated lesions) when checkpoint inhibitors are applied 
with or after radiotherapy in some cancers.
The notion that immunotherapy is changing the 
fundamentals and clinical practice of radiotherapy, 
however, is, to say the least, premature and cannot 
be derived from available data. True improvements 
of radiotherapy aim to widen the therapeutic window 
between the chance to eradicate the tumour (or 
metastases) and the risk of inducing normal tissue 
damage. A fundamental change of radiotherapy, for 
example, would be if immunotherapy allowed radiation 
oncologists to reduce the radiation dose to the tumour 
substantially without decreasing the chance of local 
control. In this case, healthy tissues could be better 
spared from the detrimental effects of radiation if the 
immune stimulatory effects were restricted to the tumour 
tissue. Immunotherapy could also widen the therapeutic 
window if healthy tissues were spared through reduced 
margin around the tumour, or if abscopal effects could 
be enhanced substantially. These effects have not been 
tested or shown by the seminal studies reported so far. 
For example, a secondary analysis of the KEYNOTE-001 
phase 1 trial evaluated patients who received 
radiotherapy (not part of the trial) for locally advanced 
or metastatic non-small-cell lung cancer (NSCLC) 
before receiving pembrolizumab. Progression-free, and 
overall survival were significantly longer in irradiated 
patients, but treatment-related lung toxicity appeared 
to be increased; however, the study was not sufficiently 
powered to answer this question. Selection bias for 
more indolent disease in the irradiated group cannot be 
excluded as the time interval between initial diagnosis 
and receipt of pembrolizumab was significantly longer 
in patients after radiotherapy than for patients who had 
not previously had radiotherapy. The randomised PACIFIC 
phase 3 trial showed significantly longer progression-
free and overall survival when durvalumab was given 
after standard platinum-based radiochemotherapy in 
stage III unresectable NSCLC. Pneumonitis was higher 
after checkpoint inhibition; however, the proportion 
of grade 3 and 4 pneumonitis events was similar in 
both groups. The randomised PEMBRO-RT phase 2 trial 
showed that stereotactic body radiotherapy delivered to a 
single tumour site enhanced the effect of pembrolizumab 
in non-irradiated lesions of metastatic NSCLC, but 
the results did not meet the preset endpoint criteria 
for meaningful clinical benefit. Pneumonia occurred 
more often in the experimental group than in the 
control group. Post-hoc hypothesis generating analysis 
suggested immune-stimulating effects of radiation in 
PD-L1 negative tumours. Probably the most important 
result of these trials is that immunotherapy is also 
efficacious in patients who have previously been treated 
with radiotherapy. However, as standard radiotherapy 
schedules were applied, the studies do not answer to 
the question of whether radiotherapy can be changed 
by immunotherapy. The study designs also do not allow 
assessment of whether the effects are synergistic and 
whether the therapeutic window is widened. It also 
remains unclear whether immunotherapy might be 
equally effective when delayed and restricted to tumour 
progression after radiotherapy.
Taken together, preclinical and clinical studies so 
far do not provide evidence that the fundamental 
concepts of radiotherapy will be changed by immuno-
therapy. Better understanding of the interactions of 
radiotherapy with immune responses and immuno-
therapy remains an important challenge for future 
research. In our view, changes in clinical practice for 
radiotherapy are only justified in the context of well 
designed clinical trials.
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